BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8609155)

  • 1. Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
    Schröder J; Esteban M; Müller MR; Kasimir-Bauer S; Bamberger U; Heckel A; Seeber S; Scheulen ME
    J Cancer Res Clin Oncol; 1996; 122(5):307-12. PubMed ID: 8609155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
    Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
    Liu Z; Lheureux F; Pouliot JF; Heckel A; Bamberger U; Georges E
    Mol Pharmacol; 1996 Sep; 50(3):482-92. PubMed ID: 8794885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative.
    Beck JF; Buchholz F; Ulrich WR; Boer R; Sanders KH; Niethammer D; Gekeler V
    Cancer Lett; 1998 Jul; 129(2):157-63. PubMed ID: 9719457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole.
    Jansen WJ; Pinedo HM; Kuiper CM; Lincke C; Bamberger U; Heckel A; Boven E
    Ann Oncol; 1994 Oct; 5(8):733-9. PubMed ID: 7826906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
    Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
    Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
    Nüssler V; Gieseler F; Zwierzina H; Gullis E; Pelka-Fleischer R; Diem H; Abenhardt W; Schmitt R; Langenmayer I; Wohlrab A; Kolb HJ; Wilmanns W
    Ann Hematol; 1997 Feb; 74(2):57-64. PubMed ID: 9063374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group.
    Paietta E; Andersen J; Racevskis J; Ashigbi M; Cassileth P; Wiernik PH
    Blood Rev; 1995 Mar; 9(1):47-52. PubMed ID: 7540903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
    Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Wessels H; de Witte T
    Blood; 1999 Oct; 94(7):2414-23. PubMed ID: 10498614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
    Mankhetkorn S; Garnier-Suillerot A
    Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
    Marcelletti JF; Sikic BI; Cripe LD; Paietta E
    Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
    den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
    Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
    Pea F; Damiani D; Michieli M; Ermacora A; Baraldo M; Russo D; Fanin R; Baccarani M; Furlanut M
    Eur J Clin Pharmacol; 1999 Jul; 55(5):361-8. PubMed ID: 10456485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
    Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.
    Khamenehfar A; Gandhi MK; Chen Y; Hogge DE; Li PC
    Anal Chem; 2016 Jun; 88(11):5680-8. PubMed ID: 27149245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult acute myeloid leukemias].
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Guerci O
    Ann Biol Clin (Paris); 1996; 54(1):17-9. PubMed ID: 8731790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
    Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
    Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.